The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells

SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Rothan, Hussin A., Stone, Shannon, Natekar, Janhavi, Kumari, Pratima, Arora, Komal, Kumar, Mukesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236683/
https://www.ncbi.nlm.nih.gov/pubmed/32442105
http://dx.doi.org/10.1016/j.virol.2020.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236683/
https://www.ncbi.nlm.nih.gov/pubmed/32442105
http://dx.doi.org/10.1016/j.virol.2020.05.002

Ejemplares similares